Mother to Child Transmission of Antibody to Covid-19 The TRAB CoV-19 Study.

This is a prospective clinical study aiming to investigate on the transplacental antibody transmission post Covid-19 infection during pregnancy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Antibody COVID-19 Cone-Rod Dystrophies Congenital, Hereditary, and Neonatal Diseases and Abnormalities Cord Coronaviridae Infections Coronavirus Infections Eye Diseases Eye Diseases, Hereditary Genetic Diseases, Inborn Infections Lung Diseases Maternal Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Retinal Degeneration Retinal Diseases Retinal Dystrophies Vaccine Virus Diseases

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Observational

Primary location

UKM Medical Center

Kuala Lumpur, W.Persekutuan, 56000, Malaysia

About this study

Covid -19 infection has been a significant public health burden as it shifted the paradigm of infectious diseases aiming to control the spread and enhance public immune protection. The introduction of Covid -19 vaccination in December 2020 aimed to combat the infection, thus tremendously helping to flatten the disease worldwide. Channeling the vaccine for the obstetrics field is one of the hallmark strategies to reduce maternal morbidity and mortality. The efficacy of vaccination for the pregnant lady has been established. However, fetus protection via transmission of the antibody during pregnancy is still uncertain. Therefore, this study aims to consolidate further evidence of transplacental antibody post-maternal vaccination aiming for fetal protection following delivery.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

term pregnancies at 37 weeks or more
vaccinated 2 doses
in labour

Exclusion criteria

unvaccinated
preterm labour less than 37 weeks
multiple pregnancies

Treatment and study plan

Primary outcomes

Maternal to Neonatal Transmission Antibody Covid-19 Study - The TRAB CoV-19

Time frame: 30 minutes after delivery

Quantification of Covid-19 antibody levels in maternal and cord blood samples

Sponsors and collaborators

Lead sponsor

National University of Malaysia

Other

Collaborators

Malaysia Automotive Robotics and Innovation of Technology Institute

Registry information

Official study title

Maternal to Neonatal Transmission Antibody Covid-19 Study - The TRAB CoV-19

Important dates

Study start: 2021
Primary completion: 2022
Study completion: 2022
First posted: Mar 31, 2022
Registry last updated: Apr 8, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed